CME Is Down 25% in 76 Days. What History Says Now

CME Group Is Down 25% in 76 Days. Here is What History Suggests.

As of June 18, 2026, CME Group Inc. (CME) has entered a deep -24.5% drawdown from its all-time high of $326.46, crossing into the red zone with a Drawdown Severity Score™ of 5.1. History suggests that recoveries from pullbacks of this magnitude are prolonged, with the 5 previous times CME dropped 20% or more requiring an average of 951 days to recover. This price decline of -24.5% over 76 days contrasts with the stock's internal valuation metrics, as its price-to-sales (P/S) ratio of 13.6 sits in the 59th percentile of its historical record since June 19, 2006, while its EV-to-EBITDA ratio of 15.5 sits in the 30th percentile.

Current Severity and the Move to the Red Zone

Our data shows that the current decline has moved CME from the yellow zone to the red zone, representing a shift in its risk profile. With a Drawdown Severity Score™ of 5.1, the current drawdown of -24.5% is far more severe than the average historical drawdown of -4.5% observed across all 168 historical drawdown events in our database. Furthermore, the current duration of 76 days already exceeds the historical average drawdown duration of 47 days, indicating that the current selling pressure is more persistent than typical historical pullbacks.

This transition highlights a departure from the stock's historical norm. Typically, CME functions as a highly stable exchange operator with quick recovery periods, but the current 76-day stretch reflects sustained downward momentum. The crossing of the 5.1 severity score threshold places this event among the most significant pullbacks in the stock's public trading history.

Valuation Versus Its Own Record

As of the valuation snapshot on 2026-06-18, CME's valuation multiples present a mixed alignment with its price drawdown when compared against its own daily history since 2006-06-19. The current price-to-sales (P/S) ratio of 13.6 is in the 59th percentile of its daily record, placing it slightly above its historical median P/S of 12.4. Conversely, the EV-to-EBITDA ratio of 15.5 sits in the 30th percentile of its historical record, below its historical median EV-to-EBITDA of 18.6. This divergence indicates that while the sales-based multiple remains within its typical historical upper half, the cash-flow-based multiple has adjusted to the lower third of the company's historical range, providing purely historical baseline context rather than an indicator of future performance or an investment recommendation.

What History Says About 20% Drawdowns

To understand how CME has behaved during similar market phases, we analyzed past instances where the stock dropped by 20% or more from its peak. Our database shows that CME has experienced a drop of 20% or more only 5 times since 2006. The average duration of these comparable drops, from the peak to a full recovery of the previous high, is 951 days.

It is critical to note that a sample size of 5 historical events is too small to be statistically predictive of future performance. Each of those prior drawdowns occurred under unique macroeconomic conditions, interest rate environments, and regulatory landscapes, meaning the current recovery timeline could differ substantially from the historical 951-day average.

Market Catalysts and Recent News

Several fundamental developments have accompanied CME's descent into the red zone. According to a report by Yahoo Finance, the stock approached its 52-week low following a sharp 19.8% drop, intensifying discussions around near-term capital allocation. This downward pressure coincided with a major leadership transition, as Stock Titan reported that CME Group named Lynne Fitzpatrick as the incoming CEO to succeed Terry Duffy, who will exit the top job in 2027.

While leadership transitions often introduce near-term uncertainty, some analysts view the underlying business conditions favorably. Specifically, Seeking Alpha reported that Keefe, Bruyette & Woods (KBW) raised CME Group to Outperform, noting that market fears regarding perpetual futures risk were overblown. This upgrade suggests that while the equity market has priced in significant risk, institutional analysts see a discrepancy between the stock's price action and its operational outlook.

Key Fundamental Factors to Monitor

As CME trades in the red zone, market participants can observe specific fundamental triggers to gauge the business's operational health. First, trading volumes in interest rate futures and options remain crucial, as changes in central bank interest rate policies directly impact hedging volumes. Second, commodity clearing volumes, particularly in core agricultural contracts like Lean Hog and Soybean futures, provide a direct measure of transaction fee revenue.

Additionally, the execution of the CEO transition plan leading up to 2027 and the competitive dynamics of the treasury clearing mandate will be key factors influencing institutional sentiment. Monitoring how these operational metrics evolve relative to the historical valuation percentiles will help clarify whether the current drawdown is a temporary dislocation or a structural shift.